Progressive relapsing multiple sclerosis
Therapeutic area
Immunology
Rare disease
No
- Definition
- A multiple sclerosis that is characterized by steadily worsening symptoms and attacks during periods of remission with disease progression from the onset.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Progressive relapsing multiple sclerosis
- Alternative names
- progressive relapsing multiple sclerosis
- Therapeutic area
- Immunology
- Disease mechanisms
- Developmental
- Severity
- Severe
- Immunology
- Neurology
- MONDO ID
- MONDO:0000452
- Parent condition
- MONDO:0005284
Related records
Broader conditions (18)
- Autoimmune disease
- Autoimmune disorder of central nervous system
- Autoimmune disorder of the nervous system
- Brain disorder
- Central nervous system disorder
- Chronic progressive multiple sclerosis
- CNS demyelinating autoimmune disease
- Demyelinating disease
- Demyelinating disease of central nervous system
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disorder of development or morphogenesis
- Human disease
- Immune system disorder
- Multiple sclerosis
- Nervous system disorder
- Neurodegenerative disease
Trials (99)
- 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
- A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
- A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
- A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
- A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability
- A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
- A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
- A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
- A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
- A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)
- A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
- A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
- A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
- A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
- A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis